Baricitinib

CAS : 1187594-09-7

Ref. 3D-FE30357

Informations sur le produit

• Nom: Baricitinib
• Synonymes: INCB 0280501-(Ethylsulfonyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]-3-azetidineacetonitrileLY 3009104, 1-(Ethylsulfonyl)-3-[4-(7H-pyrrolo[2,3-d]pyriMidin-4-yl)-1H-pyrazol-1-yl]-3-azetidineacetonitrile, 2-(3-(4-(3H-Pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-1-(ethylsulfonyl)azetidin-3-yl)acetonitrile, 2-(3-(4-(7H-Pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-1-(ethylsulfonyl)azetidin-3-yl)acetonitrile, 3-Azetidineacetonitrile, 1-(ethylsulfonyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]-, Incb 028050, Incb 28050, Incb028050, Ly 3009104, Ly3009104, Olumiant

Description

Baricitinib is a Janus kinase inhibitor (JAK) currently used as monotherapy in the treatment of rheumatoid arthritis. Barictinib is also recommened for the treatment of atopic dermatitis and systemic lupus erythematosus. In mice interestingly, the administration of baricitinib reduced the inflammatory effects induced by a high-sugar diet on the metabolism.

• Marque: Biosynth

Propriétés chimiques

• Masse moléculaire: 371.42 g/mol
• Formule: C₁₆H₁₇N₇O₂S
• Degré de pureté: Min. 95%
• Couleur/Forme: Powder
• SMILES: CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1